GSK plc’s daprodustat has won US Food and Drug Administration approval for the treatment of chronic kidney disease (CKD) patients with anemia under the brand name Jesduvroq, but a limited label has put a dampener on its future prospects.
Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.
